Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02486120
Other study ID # 999915152
Secondary ID 15-HG-N152
Status Completed
Phase
First received
Last updated
Start date June 22, 2015
Est. completion date May 24, 2017

Study information

Verified date May 24, 2017
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- Suicide is one of the main causes of death for adolescents in the U.S. The most effective way to decrease suicide is by training doctors to recognize the risk factors in their clients. One risk factor for suicide is chronic illness. So pediatric genetic counselors come across high-risk clients. But the suicide risk assessment (SRA) practices of these counselors are not well known. Researchers want to study learn more about this.

Objectives:

- To describe the practices, attitudes, and beliefs of genetic counselors about SRA of adolescents.

Eligibility:

- Genetic counselors who see adolescents ages 10 21

Design:

- A study will be open to a listserv for genetic counselors.

- Participants will take a survey on their own.

- The survey will be online on a secure website.

- Participants will give data about themselves. This can include age, gender, job, etc.

- The survey will be about 60 questions.

- The survey will take around 20 25 minutes.

- The questions are about participants experiences, practices, attitudes, and beliefs about SRA.


Description:

This study proposes to describe the practices, attitudes, and beliefs of genetic counselors in relation to suicide risk assessment (SRA) of their adolescent clients. Suicide is a major public health issue and one of the leading causes of death for adolescents in the U.S. Analysis of suicide prevention campaigns has shown that the most effective way to decrease suicide is by training physicians to recognize suicide risk factors in their patients . However, pediatricians do not consistently screen youth for suicide risk during routine check-ups. As chronic illness is an additional risk factor for suicide, pediatric genetic counselors encounter particularly high-risk clients and are well-positioned to assess for suicide risk due to the psychosocial nature of their work. However, the SRA practices of genetic counselors are largely unknown. In this study, the Transtheoretical Model of Behavior Change is used as a framework to describe how genetic counselors SRA self-efficacy and perceptions of the pros and cons of SRA relate to stages of readiness and practices of assessing clients for suicide risk. Specifically, we will be surveying genetic counselors about their practices, attitudes and beliefs concerning SRA of adolescent clients. First, we will determine genetic counselors frequency of SRA and their stage of readiness for routine screening. Second, we will measure genetic counselors SRA self-efficacy and their perceptions of the pros and cons of screening their clients. We will examine whether self-efficacy and perceptions of pros and cons are predictors of genetic counselors stage of readiness for routine suicide screening. Finally, we will qualitatively assess genetic counselors perceptions of the usability of a validated suicide screening tool (the ASQ) in genetic counseling sessions and their interest in receiving suicide screening training. We will use a cross-sectional, mixed-methods design in which counselors will complete an online questionnaire with quantitative components and open-ended responses. Participants will be recruited through the National Society of Genetic Counselors Student Research Survey listserv.


Recruitment information / eligibility

Status Completed
Enrollment 267
Est. completion date May 24, 2017
Est. primary completion date May 31, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility - INCLUSION CRITERIA:

Participants in this study will be English speaking women and men who are graduates of accredited genetic counseling programs. Those who currently or within the past year have worked in-person with adolescent patients between the ages of 10 and 21 may be included in the survey.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Human Genome Research Institute (NHGRI), 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Previous performance of adolescent patient suicide risk assessment Ongoing
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1